Literature DB >> 1977807

Activation of the complement system in human immunodeficiency virus infection: relevance of the classical pathway to pathogenesis and disease severity.

G Senaldi1, M Peakman, T McManus, E T Davies, D E Tee, D Vergani.   

Abstract

In vitro studies implicate classical and alternative complement pathway activation in the pathogenesis of human immunodeficiency virus (HIV) infection. To ascertain their importance in vivo, activation fragments of the classical (C4d), alternative (Ba), and common (C3d) pathways were measured and fragment to parent molecule ratios derived in 74 HIV-infected individuals and related to circulating immune complex (CIC) levels, Centers for Disease Control (CDC) stage, and beta 2-microglobulin, neopterin, and CD4-positive (CD4+) lymphocyte levels. All fragments and ratios were significantly higher in patients (P less than .01) than controls. C4 conversion indices (C4d and C4d to C4) increased linearly with increasing CDC stage (P less than .001), while CD4+ lymphocytes decreased linearly (P less than .001). C4d, C3d, C4d to C4, and C3d to C3 correlated with increasing CIC and beta 2-microglobulin, and C4d and C4d to C4 correlated with decreasing CD4+ lymphocytes (P less than .05). The relationship of classical complement pathway activation to disease progression and CD4+ lymphocytes suggests its involvement in the pathogenesis of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977807     DOI: 10.1093/infdis/162.6.1227

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Soluble membrane attack complex in the blood and cerebrospinal fluid of HIV-infected individuals, relationship to HIV RNA, and comparison with HIV negatives.

Authors:  Albert M Anderson; Theresa N Schein; Aley Kalapila; Lillin Lai; Drenna Waldrop-Valverde; Raeanne C Moore; Donald Franklin; Scott L Letendre; Scott R Barnum
Journal:  J Neuroimmunol       Date:  2017-07-23       Impact factor: 3.478

2.  Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked.

Authors:  Michael Huber; Viktor von Wyl; Christoph G Ammann; Herbert Kuster; Gabriela Stiegler; Hermann Katinger; Rainer Weber; Marek Fischer; Heribert Stoiber; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

3.  Inhibition of HIV replication by CD8+ T cells correlates with CD4 counts and clinical stage of disease.

Authors:  A M Gómez; F M Smaill; K L Rosenthal
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

Review 4.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

Review 5.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

6.  Effect of human immunodeficiency virus infection on plasma bactericidal activity against Salmonella enterica serovar Typhimurium.

Authors:  Estela Trebicka; Nanda Kumar N Shanmugam; Anastassia Mikhailova; Galit Alter; Bobby J Cherayil
Journal:  Clin Vaccine Immunol       Date:  2014-08-13

7.  Immunoglobulin and complement complexes in blood following infection with human immunodeficiency virus type 1.

Authors:  X X Peng; M A Wainberg; Y Tao; B G Brenner
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

8.  Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques.

Authors:  Leia K Miller-Novak; Jishnu Das; Thomas A Musich; Thorsten Demberg; Joshua A Weiner; David J Venzon; Venkatramanan Mohanram; Diego A Vargas-Inchaustegui; Iskra Tuero; Margaret E Ackerman; Galit Alter; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

9.  T cell activation and disease severity in HIV infection.

Authors:  M Mahalingam; M Peakman; E T Davies; A Pozniak; T J McManus; D Vergani
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

10.  Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21).

Authors:  D C Montefiori; K Stewart; J M Ahearn; J Zhou; J Zhou
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.